---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-26-000008"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2026-01-27T23:59:59+00:00"
generated_at: "2026-05-16T07:40:15.522781+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics terminates exclusive license for certepetide with Qilu Pharmaceutical

## Summary
- Mutual termination of 2021 License and Collaboration Agreement with Qilu, effective January 23, 2026.
- Agreement covered research, development, and commercialization of certepetide (CEND-1) in Greater China.
- Lisata was eligible for up to $200M in milestone payments and 10%-15% royalties on net sales.
- Termination does not affect obligations accrued prior to termination or certain surviving provisions.
- No immediate financial impact disclosed; company loses future milestone/royalty potential.

## SEC filing metadata
- accession: 0000320017-26-000008
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2026-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001726000008/0000320017-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001726000008/clbs-20260127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-26-000008
- JSON: https://secwatch.observer/filing/0000320017-26-000008.json
- Plain text: https://secwatch.observer/filing/0000320017-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.